@article{96e3e86200e24d8aa19592939af25d68,
title = "DSM-5: A collection of psychiatrist views on the changes, controversies, and future directions",
abstract = "The recent release of the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) by the American Psychiatric Association has led to much debate. For this forum article, we asked BMC Medicine Editorial Board members who are experts in the field of psychiatry to discuss their personal views on how the changes in DSM-5 might affect clinical practice in their specific areas of psychiatric medicine. This article discusses the influence the DSM-5 may have on the diagnosis and treatment of autism, trauma-related and stressor-related disorders, obsessive-compulsive and related disorders, mood disorders (including major depression and bipolar disorders), and schizophrenia spectrum disorders.",
keywords = "Autism, Bipolar, DSM-5, Depression, Mood disorders, Obsessive-compulsive disorders, PTSD, Psychiatry, Schizophrenia",
author = "Nemeroff, {Charles B.} and Daniel Weinberger and Michael Rutter and MacMillan, {Harriet L.} and Bryant, {Richard A.} and Simon Wessely and Stein, {Dan J.} and Pariante, {Carmine M.} and Florian Seem{\"u}ller and Michael Berk and Malhi, {Gin S.} and Martin Preisig and Martin Br{\"u}ne and Paul Lysaker",
note = "Funding Information: CP receives research funding from the Medical Research Council and other governmental agencies, the National Institute of Health Research and other NHS-related funding, the Wellcome Trust and other charities, and pharmaceutical companies. Funding Information: CBN has received grants or research support from the National Institutes of Health (NIH) and Agency for Healthcare Research and Quality (AHRQ); has provided consultation for Xhale, Takeda, SK Pharma, Shire, Roche, Lilly, Allergan, and Mitsubishi Tanabe Pharma Development America; is a stockholder of CeNeRx BioPharma, PharmaNeuroBoost, Revaax Pharma, and Xhale; and has received income or equity from AstraZeneca Pharmaceuticals, PharmaNeuroBoost, CeNeRx BioPharma, NovaDel Pharma, Reevax Pharma, American Psychiatric Publishing, and Xhale. Other financial interests include CeNeRx BioPharma and PharmaNeuroBoost. CBN also holds patents for methods and devices for transdermal delivery of lithium (US 6,375,990B1) and methods of assessing anti-depressant drug therapy via transport inhibition of monoamine neurotransmitters by ex vivo assay (US 7,148,027B2). He is also on the scientific advisory boards of American Foundation for Suicide Prevention (AFSP), CeNeRx BioPharma (2012), National Alliance for Research on Schizophrenia and Depression (NARSAD), Xhale, PharmaNeuroBoost (2012), Anxiety Disorders Association of America (ADAA), Skyland Trail, and AstraZeneca Pharmaceuticals (2009); and is on the board of directors of AFSP, Mt. Cook Pharma (2010), NovaDel (2011), Skyland Trail, Gratitude America, and ADAA. DW has no competing interests to declare. Funding Information: Harriet L. MacMillan is Professor in the Departments of Psychiatry and Behavioural Neurosciences and in the Department of Pediatrics, Chedoke Health Chair in Child Studies and Acting Director of Offord Centre for Child Studies at McMaster University and McMaster Children{\textquoteright}s Hospital/ Hamilton Health Sciences. She is a pediatrician and child psychiatrist, and her research interests include research into family violence and trials of interventions aimed at prevention of child maltreatment and intimate partner violence. She is supported by the Chedoke Health Chair in Child Psychiatry.",
year = "2013",
month = sep,
day = "12",
doi = "10.1186/1741-7015-11-202",
language = "English (US)",
volume = "11",
journal = "BMC medicine",
issn = "1741-7015",
publisher = "BioMed Central",
number = "1",
}